OTCMRICFY
Market cap10bUSD
Dec 19, Last price
13.06USD
1D
-2.14%
1Q
-6.48%
Name
Recordati Industria Chimica e Farmaceutica SpA
Chart & Performance
Profile
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 2,082,331 12.36% | 1,853,307 17.29% | 1,580,074 9.06% | |||||||
Cost of revenue | 1,516,564 | 1,358,997 | 1,074,754 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 565,767 | 494,310 | 505,320 | |||||||
NOPBT Margin | 27.17% | 26.67% | 31.98% | |||||||
Operating Taxes | 101,822 | 89,099 | 77,383 | |||||||
Tax Rate | 18.00% | 18.02% | 15.31% | |||||||
NOPAT | 463,945 | 405,211 | 427,937 | |||||||
Net income | 389,214 24.61% | 312,336 -19.08% | 385,966 8.73% | |||||||
Dividends | (245,958) | (230,602) | (216,742) | |||||||
Dividend yield | 2.41% | 2.85% | 1.83% | |||||||
Proceeds from repurchase of equity | 7,387 | (38,619) | (59,308) | |||||||
BB yield | -0.07% | 0.48% | 0.50% | |||||||
Debt | ||||||||||
Debt current | 110,181 | 374,971 | 231,718 | |||||||
Long-term debt | 1,380,853 | 1,363,120 | 775,564 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 21,239 | 19,418 | 21,010 | |||||||
Net debt | 1,247,667 | 1,424,486 | 728,580 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 485,319 | 461,691 | 491,650 | |||||||
CAPEX | (29,687) | (96,339) | (87,360) | |||||||
Cash from investing activities | (379,618) | (767,124) | (87,499) | |||||||
Cash from financing activities | (168,914) | 341,277 | (355,943) | |||||||
FCF | 642,409 | 235,392 | 508,320 | |||||||
Balance | ||||||||||
Cash | 221,812 | 284,734 | 244,578 | |||||||
Long term investments | 21,555 | 28,871 | 34,124 | |||||||
Excess cash | 139,250 | 220,940 | 199,698 | |||||||
Stockholders' equity | 2,051,806 | 1,862,576 | 1,688,069 | |||||||
Invested Capital | 3,031,778 | 3,027,631 | 2,165,585 | |||||||
ROIC | 15.31% | 15.61% | 19.68% | |||||||
ROCE | 17.07% | 14.47% | 21.13% | |||||||
EV | ||||||||||
Common stock shares outstanding | 209,142 | 209,060 | 209,082 | |||||||
Price | 48.83 26.01% | 38.75 -31.42% | 56.50 24.64% | |||||||
Market cap | 10,212,423 26.06% | 8,101,084 -31.42% | 11,813,152 24.65% | |||||||
EV | 11,460,090 | 9,663,079 | 12,695,985 | |||||||
EBITDA | 708,437 | 620,066 | 602,905 | |||||||
EV/EBITDA | 16.18 | 15.58 | 21.06 | |||||||
Interest | 74,455 | 32,158 | 17,420 | |||||||
Interest/NOPBT | 13.16% | 6.51% | 3.45% |